Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
|Articles|January 24, 2017
Aptar Pharma launches eDose Counter for MDIs integrating a proprietary sensing technology
Author(s)Aptar
Aptar Pharma will showcase eDose Counter for MDIs integrating a proprietary sensing technology, at the Pharmapack Europe conference to be held in Paris, France on February 1-2, 2017
Advertisement
eDose Counter for MDIs
Picture courtesy of Aptar Pharma
Aptar Pharma will showcase eDose Counter for MDIs integrating a proprietary sensing technology, at the Pharmapack Europe conference to be held in Paris, France on February 1-2, 2017
Aptar Pharma – Booth N° F7
Aptar Pharma unveils its eDose Counter for metered dose inhalers (MDIs). Our patented eDose Counter for MDIs is designed to be easy-to-use and reliable, and contributes to patient compliance. Our unique sensing technology offers direct detection of the spray, which eliminates risks of miscounting. The sensing technology is versatile and compatible with any metering valve design. In addition, our eDose Counter for MDIs includes inhaler priming and medication reminders-to-use and end-of-product-life warnings (flashing digits) while remaining cost-effective.
For further information, visit
About Aptar Pharma
Aptar Pharma is part of the AptarGroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage.
AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food, and beverage markets.
AptarGroup is headquarters in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. To learn more, visit www.aptar.com/pharma
Advertisement
Related to this article
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement